C. Nolan

Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.

C. Rudin, G. Shapiro, D. Camidge, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

G. Giaccone, C. Rudin, M. Ranson, 2012, Clinical Cancer Research.

Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study

C. Flowers, S. de Vos, L. Swinnen, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).

T. Miller, T. Kipps, A. Roberts, 2013 .

Cancer Therapy : Clinical Phase II Study of Single-Agent Navitoclax ( ABT-263 ) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

G. Giaccone, C. Rudin, G. Shapiro, 2012 .

The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I Study

A. Roberts, M. Davids, J. Pagel, 2012 .

VENETOCLAX (VEN), BENDAMUSTINE (B) AND RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL): FINAL RESULTS OF a PHASE I STUDY

L. Swinnen, S. Wong, J. Ross, 2017 .

A phase IIa study of ABT-263 in patients with relapsed small-cell lung cancer (SCLC).

C. Rudin, D. Camidge, L. Gandhi, 2010 .

Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL).

A. Roberts, M. Davids, J. Pagel, 2013 .